Impact of human immunodeficiency virus infection in patients infected with the hepatitis C virus

Liver International

Volumn 27, Issue 1, 2007, Pages 40-46

  Valle Tovo, Cristiane ^a,b   Alves de Mattos, Angelo ^a   Ribeiro de Souza, Andréa ^a   Ferrari de Oliveira Rigo, Juliana ^a   Lerias de Almeida, Paulo Roberto ^a   Galperim, Bruno ^a   Riegel Santos, Breno ^a  

^a HOSPITAL NOSSA SENHORA DA CONCEIÇÃO   (Brazil)

^b NONE   (Brazil)

Author keywords

AIDS; Hepatitis C; HIV seropositivity

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; RIBAVIRIN; VIRUS RNA;

ADULT; ANTIBODY DETECTION; ARTICLE; BLOOD ANALYSIS; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INFECTION RISK; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NONHUMAN; RISK ASSESSMENT; RISK FACTOR; RNA ANALYSIS; SUPERINFECTION; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; FEMALE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; INTERFERONS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RIBAVIRIN; RISK FACTORS; VIRAL LOAD;

EID: 33846499813     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2006.01344.x     Document Type: Article

References (60)

1. UNAIDS and WHO AIDS epidemic update. Geneva: UNAIDS and WHO, 2004.
2. Alter M J. Epidemiology of hepatitis C in the West. Semin Liver Dis 1995; 15: 5-14.
3. Di Bisceglie A M. Hepatitis C. Lancet 1998; 351: 351-5.
4. Soriano V, Garcia-Samaniego J, Rodriguez-Rosado R, Gonzalez J, Pedreira J. Hepatitis C and HIV infection: Biological, clinical, and therapeutic implications. J Hepatol 1999; 31(Suppl. 1): 119-23.
5. Bruno R, Sacchi R, Puoti M, Soriano V, Filice G. HCV chronic hepatitis in patients with HIV: Clinical management issues. Am J Gastroenterol 2002; 97: 1598-606.
6. National Institute of Health (NIH). Consensus development conference statement - management of hepatitis C. Hepatology 1997; 26(Suppl. 1): 2S-10S.
7. Quaranta J F, Delaney S R, Alleman S, Cassuto J P, Dellamonica P, Allain J P. Prevalence of antibody to hepatitis C virus in HIV-1 infected patients. J Med Virol 1994; 42: 29-32.
8. Zanetti A R, Tanzi E, Paccagnini S, et al. Mother to infant transmission of hepatitis C virus. Lancet 1995; 345: 289-91.
9. Spengler U, Rockstroh J K. Hepatitis C in the patient with human immunodeficiency virus infection. J Hepatol 1998; 29: 1023-30.
10. Rodriguez-Mendez M L, Gonzalez-Quintela A, Aguilera A, Carballo E, Barrio E. Association of HCV and HBV markers in Spanish HIV-seropositive patients in relation to risk practices. Hepatogastroenterology 2003; 50: 2093-7.
11. Gow P J, Pillay D, Multimer D. Solid organ transplantation in patients with HIV infection. Transplantation 2001; 72: 177-81.
12. Sherman K E, Roustrer S, Chung R, Rajicic N. Hepatitis C: Prevalence in HIV-infected patients across sectional analysis of the US ACTG. Antivir Ther 2000; 5: 64-5.
13. Sherman K E, Rouster S D, Chung R T, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: A cross-sectional analysis of the US Adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34: 831-7.
14. Soriano V, Sulkowski M, Bergin C, et al. Care of patients with chronic hepatitis C and HIV co-infection: Recommendations from the HIV-HCV International Panel. AIDS 2002; 16: 813-28.
15. Martin-Carbonero L, Soriano V, Valencia M E, López M, González-Lahoz J. Impact of chronic viral hepatitis on hospital admission and mortality in HIV-infected patients. AIDS Res Hum Retroviruses 2001; 17: 1467-71.
16. Puoti M, Spineti A, Ghezzi A. Mortality for liver disease in patients with HIV infection: A cohort study. AIDS Res Hum Retroviruses 2001; 17: 146-71.
17. Di Martino V, Rufat P, Boyer N, et al. The influence of human immunodeficiency virus co-infection on CHRONIC hepatitis C in injection drug users: A long-term retrospective cohort study. Hepatology 2001; 34: 1193-9.
18. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-32.
19. Bedossa P, Poynard T. METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996; 24: 289-93.
20. Benhamou Y, Bochet M, Di Martino V, et al. The MULTIVIRC Group. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus co-infected patients. Hepatology 1999; 30: 1054-8.
21. Benhamou Y, Di Martino V, Bochet M, et al. Factors affecting liver fibrosis in human immunodeficiency virus and hepatitis C virus co-infected patients. Impact of protease inhibitor therapy. Hepatology 2001; 34: 283-7.
22. National Institute of Health (NIH). Consensus development conference statement - Management of hepatitis C. Gastroenterology 2002; 123: 2082-99.
23. Chung R T, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV co-infected persons. N Engl J Med 2004; 351: 451-9.
24. Torriani F, Rodriguez-Torres M, Rockstroh J K, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients (APRICOT). N Engl J Med 2004; 351: 438-50.
25. Alberti A, Clumeck N, Collins S, et al. Short statement of the first European consensus conference on the treatment of chronic hepatitis C and B in HIV co-infected patients. J Hepatol 2005; 42: 615-24.
26. Jackson J B, Parsons J S, Nichols L S, Knoble N, Kennedy S, Piwowar E M. Detection of human immunodeficiency virus type 1 (HIV-1) antibody by western blotting and HIV-1 DNA by PCR in patients with AIDS. J Clin Microbiol 1997; 35: 1118-21.
27. Germer J J, Heimgastner P J, Ilstrup D M, Harmsen W S, Jenkins G D, Patel R. Comparative evaluation of the VERSANT HCV RNA 3.0, QUANTIPLEX HCV RNA 2.0 and COBAS AMPLICOR HCV MONITOR version 2.0 assays for quantification of hepatitis C virus RNA in serum. J Clin Microbiol 2002; 40: 495-500.
28. Halfon P, Ouzan D, Cattan L, Cacoub P. The diagnostic tools of hepatitis C virus infections. Presse Med 2004; 33: 538-41.
29. World Health Organization. Hepatitis C global prevalence (update). Wkly Epidemiol Rec 2000; 75: 17-28.
30. Soriano V, Rodriguez-Rosado R, Garcia-Samaniego J. Management of chronic hepatitis C in HIV-infected patients. AIDS 1999; 13: 539-46.
31. Rockstroh J K. Management of hepatitis C/HIV coinfection. Curr Opin Infect Dis 2006; 19: 8-13.
32. Thomas D L, Astemborski J, Rai R M, et al. The natural history of hepatitis C virus infection: Host, viral and environmental factors. JAMA 2000; 284: 450-6.
33. Myers R P, Benhamou Y, Boche M, Thibault V, Mehri D, Poynard T. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus co-infected non-responders and relapsers to IFN-based therapy. AIDS 2004; 18: 75-9.
34. Sabin C A, Telfer P, Phillips N A, Bhagani S, Lee C A. The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men. J Infect Dis 1997; 175: 164-8.
35. Ibrahim A, Shpaner A, Nieto J, Saag S. Risk factors of accelerated liver fibrosis in HIV/CHV co-infection: A matched analysis [abstract]. Liver Int 2004; 24(Suppl. 4): 30.
36. Forns X, Ampurdanés X, Llovet J, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986-92.
37. Martin-Carbonero L, Benhamou Y, Puoti M, et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: A European collaborative study. Clin Infect Dis 2004; 38: 1789-90.
38. Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26: 1-5.
39. Kramer J R, Giordano T P, Souchek J, Richardson P, Hwang L Y, El-Serag H B. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in US veterans with hepatitis C. Am J Gastroenterol 2005; 100: 56-63.
40. Brau N, Salvatore M, Rios-Bedoya C F, et al. Slower fibrosis progression in HIV/HCV coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44: 47-55.
41. Both C T, Rossa I, Segura E S, Dalla-Costa J, Chaves A L, Mattos A A. Prevalência e implicações do vírus da hepatite c em alcoolistas. Rev AMRIGS 1996; 40: 217-20.
42. Lauer G M, Walker B D. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
43. Greub G, Ledengerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus co-infection: The Swiss HIV Cohort Study. Lancet 2000; 356: 1800-5.
44. Piroth L, Duong M, Quantin C, et al. Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients. AIDS 1998; 12: 381-8.
45. Dorucci M, Pezzotti P, Phillips N A, Lepri A C, Rezza G (for the Italian Seroconversion Study). Co-infection of hepatitis C virus with immunodeficiency virus and progression to AIDS. J Infect Dis 1995; 172: 1503-8.
46. Wright T L, Hollander H, Pu X, et al. Hepatitis C in HIV-infected patients with and without AIDS: Prevalence and relationship to patient survival. Hepatology 1994; 20: 1152-5.
47. Soriano V, Puoti M, Sulkowski M, et al. Care of patients with hepatitis C and HIV co-infection. AIDS 2004; 18: 1-12.
48. Soriano V, MiróJ M, Garcia-Samaniego J, et al. V Consensus conference on chronic viral hepatitis and HIV infection: Updated Spanish recommendations. J Viral Hepatitis 2004; 2-17.
49. Strader D B, Wright T, Thomas D L, Seeff L B. Diagnosis, management and treatment of hepatitis C. Hepatology 2004; 39: 1147-71.
50. Pérez-Olmeda M, Nunez M, Romero M, et al. Pegylated IFN-a2b plus RBV as therapy for chronic hepatitis C in HIV-infected patients. AIDS 2003; 17: 1023-8.
51. Bochet M, De Torres M, Valantin M. Efficacy and tolerance of interferon plus ribavirin for chronic hepatitis C in HIV infected patients (abstract). In: 8th Conference on Retroviruses and Opportunistic Infections, Chicago, 2003.
52. Landau A, Batisse D, Van Huyen J P D, et al. Efficacy and safety of combination therapy with interferon-alpha 2b and ribavirin for chronic hepatitis C in HIV-infected patients. AIDS 2000; 14: 839-44.
53. Landau A, Batisse D, Piketty C, Jian R, Kazatchkine M. Lack of interference between ribavirin and nucleoside analogues in HIV/HCV co-infected individuals undergoing concomitant anti-retroviral and anti-HCV combination therapy. AIDS 2000; 14: 1857-8.
54. Landau A, Batisse D, Piketty C, et al. Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients. AIDS 2001; 15: 1-7.
55. Morsica G, De Bona A, Foppa C U, Sitia G, Finazzi R, Lazzarin A L. Ribavirin therapy for chronic hepatitis C does not modify HIV viral load in HIV-1 positive patients under antiretroviral treatment. AIDS 2000; 14: 1656-8.
56. Nasti G, Di Genaro G, Tavio M, et al. Chronic hepatitis C in HIV infection: Feasibility and sustained efficacy of therapy with interferon alfa-2b and ribavirin. AIDS 2001; 15: 1783-7.
57. Perez-Olmeda M, Soriano V, Asensi V, et al. Treatment of chronic hepatitis C in HIV-infected patients with interferon alpha-2b plus ribavirin. AIDS Res Hum Retroviruses 2003; 19: 1083-9.
58. Sauleda S, Juarez A, Esteban J I, et al. Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders. Hepatology 2001; 34: 1035-40.
59. Suciu L, Goldman D, Jones J, Weisz K, Dieterich D. Sustained virologic response following interferon and ribavirin therapy for hepatitis C patients who are co-infected with HIV (abstract). In: Program and abstracts of the 38th Conference of the Infectious Disease Society of America, New Orleans, 2000.
60. Sulkowski M. Interferon plus ribavirin for chronic hepatitis C in HIV-infected individuals (abstract). In: 37th Infectious Diseases Society of America, Philadelphia, 1999.